Reshaping the HIV treatment and prevention landscape
Daprodustat (HIF-PHI): potential to be best-in-class
for anaemia of chronic kidney disease
Nobel prize winning science
Daprodustat
(HIF-PHI)
NORMOXIA
PATHWAY
VHL
OH
VHL
OH
Pro
Pro
Ubiquitin-
mediated
degredation
Ub
HIFa Asn
Ub
Ub
of HIFa
HIF Prolyl
Hydroxylase-1,2,3
Enzyme
Pro
Pro
HYPOXIA
HIFa Asn
PATHWAY
Pro
Pro
Robust clinical development programme
-
-
-
Single sponsor, single Hgb target
with active SoC comparator
Trial design, including primary MACE end-
point aligned with global regulators
No meta-analysis required
-Studies in dialysis (peritoneal, and
haemodialysis) and non-dialysis
gsk
ASCEND ND: Efficacy and CV safety
Non-dialysis (ND) patients on and not on rhEPO
ASCEND D: Efficacy and CV safety
Dialysis patients (HD, PD) on rhEPO
Full data expected in 3Q 2021
Significant market opportunity with shifting competitor
dynamics
-
Large and growing renal anemia market: 3m non-dialysis & 1.2m dialysis patients*
Transcription of
Nucleus
HIFa Asn HIF-responsive genes
MIHIFB p300 TTT
1. Visible Alpha consensus; *US/EU (2030) untreated and undertreated
SoC, standard of care; Hgb, hemoglobin;
-
-
Potential >£2bn HIF-PHI market¹, £0.5bn-1bn opportunity for daprodustat
Need for more convenient, oral options particularly in non-dialysis patients
99View entire presentation